A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07915791. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ALARMONY: A Phase 2 Randomized, Double Blind, Placebo Controlled Multi-center Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe COPD
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is for adult participants with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) who continue to experience exacerbations despite standard of care triple therapy treatment. It will assess the effectiveness and safety of two investigational drugs, GSK3862995B and GSK5784283, given together compared to a placebo in addition to standard of care.
Study identification
- NCT ID
- NCT07915791
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 279 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 29, 2026 (Actual)
- Primary completion
- Mar 7, 2029 (Estimated)
- Completion
- Feb 6, 2030 (Estimated)
- Last update posted
- Nov 17, 2026
2026 – 2030
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Newport Beach | California | 92663 | Recruiting |
| GSK Investigational Site | Miami | Florida | 33176-7016 | Recruiting |
| GSK Investigational Site | Derby | Kansas | 67037 | Recruiting |
| GSK Investigational Site | Columbia | Maryland | 21045 | Recruiting |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73111 | Recruiting |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19107 | Recruiting |
| GSK Investigational Site | Rock Hill | South Carolina | 29732 | Recruiting |
| GSK Investigational Site | Tomball | Texas | 77375 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07915791, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 17, 2026 · Synced Nov 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.